GCM
PYXS icon

Ghisallo Capital Management’s Pyxis Oncology PYXS Stock Holding History

Ghisallo Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$329K – 379
2021
Q4 		$329K Buy
+30,000
New +$343K 0.02% 422

Other funds holding PYXS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ghisallo Capital Management's PYXS Position: Q1 2022 in Review

Ghisallo Capital Management sold out of Pyxis Oncology (PYXS) in Q1 2022, closing a stake of 30,000 shares — an estimated $329K sold.

Ghisallo Capital Management first reported a position in PYXS in Q4 2021 and held it in 1 quarter. The position peaked at $329K in Q4 2021. 45 funds tracked by Wall St. Rank hold PYXS as of Q1 2022.

  • Ghisallo Capital Management reported no remaining Pyxis Oncology position as of Q1 2022 after selling out during the quarter.
  • Ghisallo Capital Management sold 30,000 Pyxis Oncology shares in Q1 2022, an estimated $329K.
  • Ghisallo Capital Management first reported a position in Pyxis Oncology in Q4 2021 and held it in 1 quarter.
  • Ghisallo Capital Management's Pyxis Oncology position peaked at $329K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2022.

Based on Ghisallo Capital Management's 13F filing for Q1 2022, filed 10 May 2022.